U.S. markets closed

Ligand Pharmaceuticals Incorporated (LGND)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
156.85-4.52 (-2.80%)
At close: 1:00PM EST
156.85 0.00 (0.00%)
After hours: 02:54PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close161.37
Bid151.00 x 900
Ask165.65 x 900
Day's Range153.48 - 162.53
52 Week Range82.25 - 219.75
Avg. Volume202,796
Market Cap2.621B
Beta (5Y Monthly)1.06
PE Ratio (TTM)38.77
EPS (TTM)4.05
Earnings DateFeb 01, 2022 - Feb 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 02, 2010
1y Target Est211.71
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-30% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for LGND

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ligand Pharmaceuticals Incorpor
    LGND: Lowering target price to $176.00LIGAND PHARMACEUTICALS has an Investment Rating of BUY; a target price of $176.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Zacks

    Ligand's (LGND) Drug-Developing Technologies Holds Potential

    Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.

  • Benzinga

    Ligand Pharmaceuticals Insider Sold Over $480K In Company Stock

    John L Higgins, Insider at Ligand Pharmaceuticals (NASDAQ:LGND), made a large insider sell on November 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Higgins sold 3,000 shares of Ligand Pharmaceuticals at a price of $160.50. The total transaction amounted to $481,500. Following the transaction, Higgins still owns 335,095 shares of the company, worth $53,065,644. Ligand Pharmaceuticals shares are trading dow

  • Investor's Business Daily

    Ligand Pharmaceuticals Sees RS Rating Rise To 92

    A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.